IDXX

IDEXX Laboratories, Inc. - 10-Q Summary (Period Ended Sept 30, 2007)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for IDEXX Laboratories, Inc., a provider of diagnostic products and services for the veterinary, water quality, and production animal markets. The report covers the three and nine months ended September 30, 2007. The company operates primarily through three reportable segments: Companion Animal Group (CAG), Water, and Production Animal Segment (PAS), with smaller operations in Dairy and Human Medical Diagnostics (OPTI Medical) grouped as "Other."

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 22% ($42.0 million) for the quarter and 24% ($130.7 million) for the nine months compared to the prior year. Growth was driven by acquisitions (contributing 8% to total revenue growth), favorable currency exchange rates (3%), and organic growth in CAG and PAS segments.
• Acquisitions: Significant acquisitions in the first nine months of 2007 included the Critical Care Division of Osmetech plc (OPTI Medical), Vita-Tech Canada Inc., and Institut Pourquier SAS. These added $86.1 million in cash payments and $18.0 million in assumed liabilities.
• Inventory Write-downs: The company recognized a $9.1 million write-down of pharmaceutical raw materials and a $1.0 million write-off of a prepaid royalty license related to the Navigator product (nitazoxanide) in the second quarter. This reduced gross profit margins by approximately 1.5% for the nine-month period.
• Debt: Short-term debt increased significantly to $77.3 million (from zero in Dec 2006) due to borrowings under a new $125 million revolving credit facility entered into in March 2007 to fund acquisitions and share repurchases.
• Operating Expenses: Operating expenses increased 29% for the quarter and 31% for the nine months, primarily due to higher personnel costs, share-based compensation, and amortization of intangible assets from acquisitions.

Guidance, Outlook, and Risks

• Stock Split: On October 25, 2007, the Board approved a 2-for-1 stock split to be effected as a 100% stock dividend in November 2007. Historical per-share data will be restated.
• Navigator Product Risk: The company expects to discontinue the Navigator product in 2009 due to manufacturing limitations and lower-than-projected sales. A new product is in development to replace it.
• Regulatory Risks: The company faces potential revenue loss in the UK water testing market starting in 2009 due to regulatory changes regarding Cryptosporidia testing. Additionally, FDA approval is required for new pharmaceutical products to replace current inventory.
• Legal Proceedings: The company successfully defended against an antitrust lawsuit filed by Cyntegra, Inc., with the court granting summary judgment in IDEXX's favor in October 2007.
• Liquidity: Management believes cash, operating cash flows, and the credit facility are sufficient to fund operations and strategic growth. Capital expenditures for 2007 are estimated at $65-$70 million.

Investor Verification Checklist

• Navigator Product Transition: Verify the timeline and commercial viability of the replacement product for Navigator to assess future pharmaceutical revenue stability.
• Acquisition Integration: Monitor the integration and performance of recent acquisitions (OPTI Medical, Vita-Tech, Pourquier) to ensure they meet projected revenue and margin targets.
• Debt Utilization: Track the utilization of the $125 million credit facility and the company's leverage ratio relative to the 3-to-1 covenant.
• Regulatory Changes: Assess the impact of the UK regulatory changes on water testing revenue and the progress of FDA approvals for new veterinary pharmaceuticals.
• Distributor Inventory: Review distributor inventory levels, as fluctuations can distort reported revenue growth relative to actual end-user demand.